FDA Approves Empaveli for Rare Kidney Diseases

Follow Drugslib on

By Lori Solomon HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

FRIDAY, Aug. 1, 2025 -- The U.S. Food and Drug Administration has approved Empaveli (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).

The drug has been approved for patients 12 years and older and works to reduce proteinuria with these rare diseases that affect the filtering units in the kidneys.

The approval is supported by the phase 3 VALIANT study, in which patients taking Empaveli had a 68 percent reduction in proteinuria, a stabilization of kidney function, and a substantial clearance of C3 deposits (measured by C3 staining) compared with placebo. Among Empaveli-treated patients, 71 percent achieved zero C3 staining intensity, showing complete clearance of C3 deposits. The results were consistent across adolescent and adult patients for both C3G and primary IC-MPGN, as well as in C3G patients with posttransplant disease recurrence.

The most common adverse events seen with Empaveli were infusion site reactions, fever, inflammation of the nasal passages and throat, influenza, cough, and nausea.

"With standard of care, patients living with these rare and severe diseases frequently progress to kidney failure, necessitating lifelong dialysis and/or a kidney transplant," Carla Nester, M.D., lead principal investigator for the VALIANT study from the University of Iowa in Iowa City, said in a statement. "Given the urgent need, particularly in children, the approval of Empaveli marks a pivotal moment in the treatment of rare kidney diseases."

Approval of Empaveli was granted to Apellis Pharmaceuticals.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-08-02 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords